William Blair Issues Pessimistic Forecast for CVRx Earnings

CVRx, Inc. (NASDAQ:CVRX) – Stock analysts at William Blair cut their FY2025 earnings estimates for shares of CVRx in a report released on Thursday, November 6th. William Blair analyst B. Vazquez now forecasts that the company will post earnings of ($2.01) per share for the year, down from their previous forecast of ($1.98). The consensus estimate for CVRx’s current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx’s Q4 2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.97) EPS.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. The firm had revenue of $14.69 million during the quarter, compared to the consensus estimate of $14.16 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS.

A number of other brokerages have also recently commented on CVRX. Weiss Ratings reiterated a “sell (e+)” rating on shares of CVRx in a research note on Thursday, October 30th. Canaccord Genuity Group upped their target price on CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Cantor Fitzgerald increased their target price on CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, CVRx has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

CVRx Stock Down 3.4%

Shares of NASDAQ CVRX opened at $9.71 on Monday. CVRx has a 52 week low of $4.30 and a 52 week high of $18.55. The stock’s fifty day moving average is $8.74 and its 200 day moving average is $7.57. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The stock has a market capitalization of $253.94 million, a P/E ratio of -4.62 and a beta of 1.28.

Hedge Funds Weigh In On CVRx

Several large investors have recently added to or reduced their stakes in CVRX. Principal Financial Group Inc. purchased a new stake in shares of CVRx during the first quarter worth $731,000. Whittier Trust Co. purchased a new stake in CVRx during the 1st quarter worth about $73,000. Larson Financial Group LLC bought a new position in CVRx in the 1st quarter worth about $28,000. GSA Capital Partners LLP purchased a new position in CVRx during the 1st quarter valued at about $675,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of CVRx by 12.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 41,905 shares of the company’s stock valued at $512,000 after buying an additional 4,751 shares during the period. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.